KR20230129230A - Bcl11a의 표적화를 위한 조성물 및 방법 - Google Patents
Bcl11a의 표적화를 위한 조성물 및 방법 Download PDFInfo
- Publication number
- KR20230129230A KR20230129230A KR1020237022391A KR20237022391A KR20230129230A KR 20230129230 A KR20230129230 A KR 20230129230A KR 1020237022391 A KR1020237022391 A KR 1020237022391A KR 20237022391 A KR20237022391 A KR 20237022391A KR 20230129230 A KR20230129230 A KR 20230129230A
- Authority
- KR
- South Korea
- Prior art keywords
- sequence
- seq
- grna
- casx
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract 150
- 102100022976 B-cell lymphoma/leukemia 11A Human genes 0.000 title claims 57
- 101000903703 Homo sapiens B-cell lymphoma/leukemia 11A Proteins 0.000 title claims 57
- 230000008685 targeting Effects 0.000 title claims 42
- 239000000203 mixture Substances 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 56
- 108020004707 nucleic acids Proteins 0.000 claims abstract 40
- 102000039446 nucleic acids Human genes 0.000 claims abstract 40
- 101100493741 Homo sapiens BCL11A gene Proteins 0.000 claims abstract 36
- 108091033409 CRISPR Proteins 0.000 claims abstract 15
- 208000034737 hemoglobinopathy Diseases 0.000 claims abstract 10
- 238000010354 CRISPR gene editing Methods 0.000 claims abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 7
- 201000010099 disease Diseases 0.000 claims abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 4
- 210000004027 cell Anatomy 0.000 claims 82
- 239000002245 particle Substances 0.000 claims 51
- 108090000623 proteins and genes Proteins 0.000 claims 51
- 102000004169 proteins and genes Human genes 0.000 claims 50
- 235000018102 proteins Nutrition 0.000 claims 47
- 239000013598 vector Substances 0.000 claims 47
- 108091005880 Hemoglobin F Proteins 0.000 claims 29
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 25
- 230000000295 complement effect Effects 0.000 claims 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 15
- 210000004369 blood Anatomy 0.000 claims 15
- 239000008280 blood Substances 0.000 claims 15
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 14
- 108010016797 Sickle Hemoglobin Proteins 0.000 claims 12
- 239000002773 nucleotide Substances 0.000 claims 11
- 125000003729 nucleotide group Chemical group 0.000 claims 11
- 210000003743 erythrocyte Anatomy 0.000 claims 9
- 238000003780 insertion Methods 0.000 claims 9
- 230000037431 insertion Effects 0.000 claims 9
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 8
- 238000012986 modification Methods 0.000 claims 8
- 230000004048 modification Effects 0.000 claims 8
- 239000013607 AAV vector Substances 0.000 claims 7
- 108020004414 DNA Proteins 0.000 claims 7
- 108010054147 Hemoglobins Proteins 0.000 claims 7
- 102000001554 Hemoglobins Human genes 0.000 claims 7
- 101710163270 Nuclease Proteins 0.000 claims 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 238000003776 cleavage reaction Methods 0.000 claims 6
- 239000007924 injection Substances 0.000 claims 6
- 238000002347 injection Methods 0.000 claims 6
- 230000007017 scission Effects 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 6
- 210000003527 eukaryotic cell Anatomy 0.000 claims 5
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- 241000283984 Rodentia Species 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 230000005782 double-strand break Effects 0.000 claims 4
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 230000001105 regulatory effect Effects 0.000 claims 4
- 230000007018 DNA scission Effects 0.000 claims 3
- 101710170658 Endogenous retrovirus group K member 10 Gag polyprotein Proteins 0.000 claims 3
- 101710186314 Endogenous retrovirus group K member 21 Gag polyprotein Proteins 0.000 claims 3
- 101710162093 Endogenous retrovirus group K member 24 Gag polyprotein Proteins 0.000 claims 3
- 102100039715 Endogenous retrovirus group K member 6 Gag polyprotein Human genes 0.000 claims 3
- 101710094596 Endogenous retrovirus group K member 8 Gag polyprotein Proteins 0.000 claims 3
- 101710177443 Endogenous retrovirus group K member 9 Gag polyprotein Proteins 0.000 claims 3
- 101710177291 Gag polyprotein Proteins 0.000 claims 3
- 108020005004 Guide RNA Proteins 0.000 claims 3
- 101710203526 Integrase Proteins 0.000 claims 3
- 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 claims 3
- 206010043391 Thalassaemia beta Diseases 0.000 claims 3
- 210000001185 bone marrow Anatomy 0.000 claims 3
- 238000003197 gene knockdown Methods 0.000 claims 3
- 210000003734 kidney Anatomy 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 210000003643 myeloid progenitor cell Anatomy 0.000 claims 3
- 208000007056 sickle cell anemia Diseases 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 2
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 2
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 2
- 206010001580 Albuminuria Diseases 0.000 claims 2
- 108090000565 Capsid Proteins Proteins 0.000 claims 2
- 102100023321 Ceruloplasmin Human genes 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 2
- 108060003393 Granulin Proteins 0.000 claims 2
- 206010018910 Haemolysis Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 claims 2
- 208000009869 Neu-Laxova syndrome Diseases 0.000 claims 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 2
- 102000004389 Ribonucleoproteins Human genes 0.000 claims 2
- 108010081734 Ribonucleoproteins Proteins 0.000 claims 2
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 claims 2
- 241000700584 Simplexvirus Species 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 238000005534 hematocrit Methods 0.000 claims 2
- 230000008588 hemolysis Effects 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 230000010354 integration Effects 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 claims 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims 1
- 241000649045 Adeno-associated virus 10 Species 0.000 claims 1
- 101150069031 CSN2 gene Proteins 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 108700004991 Cas12a Proteins 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 241000699800 Cricetinae Species 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 108010044495 Fetal Hemoglobin Proteins 0.000 claims 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims 1
- 108060003760 HNH nuclease Proteins 0.000 claims 1
- 102000029812 HNH nuclease Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 108010081143 P8 peptide Proteins 0.000 claims 1
- 101800004193 Peptide P3 Proteins 0.000 claims 1
- 101800001494 Protease 2A Proteins 0.000 claims 1
- 101800001066 Protein 2A Proteins 0.000 claims 1
- 101800001065 Protein 2B Proteins 0.000 claims 1
- 108091034057 RNA (poly(A)) Proteins 0.000 claims 1
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 claims 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 206010003549 asthenia Diseases 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 101150055601 cops2 gene Proteins 0.000 claims 1
- 238000011161 development Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000925 erythroid effect Effects 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 claims 1
- 238000010362 genome editing Methods 0.000 claims 1
- 108700026078 glutathione trisulfide Proteins 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229910000614 lithium tin phosphorous sulfides (LSPS) Inorganic materials 0.000 claims 1
- 210000003924 normoblast Anatomy 0.000 claims 1
- 230000009438 off-target cleavage Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000004768 organ dysfunction Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 101800002729 p12 Proteins 0.000 claims 1
- XZKAKQROJCKAOP-YWZUXTQFSA-N p20 peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 XZKAKQROJCKAOP-YWZUXTQFSA-N 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 229920002477 rna polymer Polymers 0.000 claims 1
- 230000005783 single-strand break Effects 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000009466 transformation Effects 0.000 abstract 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063120885P | 2020-12-03 | 2020-12-03 | |
| US63/120,885 | 2020-12-03 | ||
| PCT/US2021/061672 WO2022120094A2 (en) | 2020-12-03 | 2021-12-02 | Compositions and methods for the targeting of bcl11a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230129230A true KR20230129230A (ko) | 2023-09-07 |
Family
ID=81854906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237022391A Pending KR20230129230A (ko) | 2020-12-03 | 2021-12-02 | Bcl11a의 표적화를 위한 조성물 및 방법 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240026386A1 (https=) |
| EP (1) | EP4255502A4 (https=) |
| JP (1) | JP2023552379A (https=) |
| KR (1) | KR20230129230A (https=) |
| CN (1) | CN116801913A (https=) |
| AU (1) | AU2021391783A1 (https=) |
| BR (1) | BR112023010717A2 (https=) |
| CA (1) | CA3200815A1 (https=) |
| CL (2) | CL2023001593A1 (https=) |
| CO (1) | CO2023007900A2 (https=) |
| GB (1) | GB2616795B (https=) |
| IL (1) | IL303359A (https=) |
| MX (1) | MX2023006565A (https=) |
| PE (1) | PE20231177A1 (https=) |
| WO (1) | WO2022120094A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230128289A (ko) | 2020-12-03 | 2023-09-04 | 스크라이브 테라퓨틱스 인크. | 조작된 클래스 2 유형 v crispr 시스템 |
| WO2022261149A2 (en) | 2021-06-09 | 2022-12-15 | Scribe Therapeutics Inc. | Particle delivery systems |
| WO2023235888A2 (en) | 2022-06-03 | 2023-12-07 | Scribe Therapeutics Inc. | COMPOSITIONS AND METHODS FOR CpG DEPLETION |
| GB2634837A (en) | 2022-06-07 | 2025-04-23 | Scribe Therapeutics Inc | Compositions and methods for the targeting of PCSK9 |
| TW202413643A (zh) | 2022-06-07 | 2024-04-01 | 美商斯奎柏治療公司 | 用於靶向pcsk9的組合物及方法 |
| WO2023240027A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Particle delivery systems |
| US20250361525A1 (en) | 2022-06-08 | 2025-11-27 | Scribe Therapeutics Inc. | Aav vectors for gene editing |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017252023B2 (en) * | 2016-04-18 | 2024-05-02 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
| MX2019003674A (es) * | 2016-09-30 | 2021-01-08 | Univ California | Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas. |
| CN110168084A (zh) * | 2016-12-05 | 2019-08-23 | 爱迪塔斯医药公司 | 用于内源和来源DNA的单发指导RNA(ogRNA)靶向的系统和方法 |
| US20190367924A1 (en) * | 2017-02-17 | 2019-12-05 | Temple University - Of The Commonwealth System Of Higher Education | Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5 |
| CN109722414A (zh) * | 2017-10-27 | 2019-05-07 | 博雅辑因（北京）生物科技有限公司 | 一种高效制备成熟红细胞的方法以及用于制备成熟红细胞的培养基 |
| WO2019213273A1 (en) * | 2018-05-01 | 2019-11-07 | The Children's Medical Center Corporation | Enhanced bcl11a rnp / crispr delivery & editing using a 3xnls-cas9 |
| JP2021532815A (ja) * | 2018-08-07 | 2021-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | 新規Ｃａｓ１２ｂ酵素およびシステム |
-
2021
- 2021-12-02 AU AU2021391783A patent/AU2021391783A1/en active Pending
- 2021-12-02 EP EP21901487.5A patent/EP4255502A4/en active Pending
- 2021-12-02 IL IL303359A patent/IL303359A/en unknown
- 2021-12-02 WO PCT/US2021/061672 patent/WO2022120094A2/en not_active Ceased
- 2021-12-02 CN CN202180092086.3A patent/CN116801913A/zh active Pending
- 2021-12-02 GB GB2309871.8A patent/GB2616795B/en active Active
- 2021-12-02 MX MX2023006565A patent/MX2023006565A/es unknown
- 2021-12-02 CA CA3200815A patent/CA3200815A1/en active Pending
- 2021-12-02 US US18/255,172 patent/US20240026386A1/en active Pending
- 2021-12-02 PE PE2023001811A patent/PE20231177A1/es unknown
- 2021-12-02 BR BR112023010717A patent/BR112023010717A2/pt unknown
- 2021-12-02 JP JP2023533861A patent/JP2023552379A/ja active Pending
- 2021-12-02 KR KR1020237022391A patent/KR20230129230A/ko active Pending
-
2023
- 2023-06-02 CL CL2023001593A patent/CL2023001593A1/es unknown
- 2023-06-16 CO CONC2023/0007900A patent/CO2023007900A2/es unknown
-
2024
- 2024-05-27 CL CL2024001577A patent/CL2024001577A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3200815A1 (en) | 2022-06-09 |
| CO2023007900A2 (es) | 2023-06-30 |
| EP4255502A2 (en) | 2023-10-11 |
| US20240026386A1 (en) | 2024-01-25 |
| EP4255502A4 (en) | 2025-07-16 |
| GB2616795A (en) | 2023-09-20 |
| WO2022120094A2 (en) | 2022-06-09 |
| PE20231177A1 (es) | 2023-08-01 |
| JP2023552379A (ja) | 2023-12-15 |
| GB2616795B (en) | 2025-08-13 |
| GB202309871D0 (en) | 2023-08-16 |
| BR112023010717A2 (pt) | 2023-10-03 |
| CL2023001593A1 (es) | 2023-12-15 |
| WO2022120094A3 (en) | 2022-08-25 |
| AU2021391783A1 (en) | 2023-06-22 |
| MX2023006565A (es) | 2023-08-07 |
| IL303359A (en) | 2023-08-01 |
| CL2024001577A1 (es) | 2024-10-18 |
| CN116801913A (zh) | 2023-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12084692B2 (en) | Guide scaffolds | |
| KR20230129230A (ko) | Bcl11a의 표적화를 위한 조성물 및 방법 | |
| US12559743B2 (en) | Engineered guide scaffolds | |
| KR20230002401A (ko) | C9orf72의 표적화를 위한 조성물 및 방법 | |
| US20230032369A1 (en) | Compositions and methods for the targeting of htt | |
| US11535835B1 (en) | Compositions and methods for the targeting of rhodopsin | |
| EP4028522A1 (en) | Compositions and methods for the targeting of sod1 | |
| CA3163714A1 (en) | Compositions and methods for the targeting of pcsk9 | |
| KR20230129162A (ko) | 제1형 근긴장성 이영양증을 치료하기 위한 rna 표적화조성물 및 방법 | |
| KR20230127221A (ko) | Cag 반복 질환을 치료하기 위한 rna 표적화 조성물및 방법 | |
| KR20210082205A (ko) | 레트로바이러스 인테그라제-Cas9 융합 단백질을 이용한 유도된 비상동 DNA 삽입에 의한 게놈 편집 | |
| US20240100185A1 (en) | Compositions and methods for the targeting of ptbp1 | |
| TW202526012A (zh) | 改良整合酶 | |
| CN117120607A (zh) | 工程化2类v型crispr系统 | |
| HK40091632A (zh) | 用於靶向bcl11a的组合物和方法 | |
| IL303360A (en) | Engineered class 2 type v crispr systems | |
| HK40076804A (en) | Compositions and methods for the targeting of pcsk9 | |
| HK40094068A (zh) | 用於靶向c9orf72的组合物和方法 | |
| EA048319B1 (ru) | СКОНСТРУИРОВАННЫЕ СИСТЕМЫ CasX |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20230630 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20241202 Comment text: Request for Examination of Application |